Human Growth Hormone vs CJC-1295 DAC.

Human growth hormone (hGH, also called somatotropin) is a 191-amino-acid, single-chain polypeptide hormone secreted by somatotroph cells of the anterior pituitary gland. The pharmaceutical form used in medicine and research is recombinant human growth hormone (rhGH, generic name somatropin), an identical 22 kDa sequence manufactured in E. coli or mammalian cells. It is one of the most studied protein hormones, marketed under brands such as Genotropin, Norditropin, Humatrope, Saizen, Nutropin, and Omnitrope.

CJC-1295 with DAC (also written DAC:GRF, CJC-1295 DAC) is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH). It is built on the bioactive N-terminal GHRH(1-29) fragment with several amino-acid substitutions, plus a "Drug Affinity Complex" (DAC): a maleimidopropionyl group that lets the peptide bind covalently to circulating albumin after injection. It was developed in the mid-2000s by ConjuChem Biotechnologies as an investigational drug; it is not an approved medicine and today circulates mainly as a research/gray-market peptide.

GH binds a single GH receptor (GHR) that dimerizes and signals through the JAK2/STAT5 pathway, driving transcription of target genes including IGF-1. Much of GH's anabolic and growth-promoting action is mediated indirectly by hepatic and local insulin-like growth factor 1 (IGF-1), while GH itself exerts direct effects that are often metabolically opposite to insulin: it stimulates lipolysis, promotes protein accretion, and induces a state of insulin resistance that raises blood glucose. Endogenous secretion is pulsatile, stimulated by hypothalamic GHRH and ghrelin and suppressed by somatostatin, with negative feedback from IGF-1 and GH itself. The net physiologic effects include longitudinal bone growth at open epiphyses, increased lean body mass, reduced fat mass, and altered glucose and lipid handling.

Like native GHRH, CJC-1295 binds the GHRH receptor on anterior pituitary somatotrophs and stimulates synthesis and pulsatile release of growth hormone (GH), which in turn drives hepatic and peripheral IGF-1 production. Two engineering features extend its action: amino-acid substitutions in the GHRH(1-29) backbone resist cleavage by dipeptidyl-peptidase-4 (DPP-4), and the DAC maleimide group forms a covalent bond with cysteine-34 of serum albumin, shielding the peptide from renal filtration and proteolysis so it persists in plasma for days rather than minutes. Because it amplifies the body's own GH axis rather than supplying exogenous GH, secretion remains somewhat pulsatile and subject to negative feedback (e.g., somatostatin).

The strongest human evidence is for replacement in diagnosed GH deficiency: recombinant somatropin is FDA-approved and supported by randomized trials and systematic reviews (e.g., Health Technology Assessment 2010, PMID 20849734, for pediatric growth disorders) showing improved growth velocity and adult height in children and improved body composition and quality of life in adult GHD (reviewed in Pituitary 2006, PMID 17077947). More recently, a long-acting analog, once-weekly somapacitan, was effective and well tolerated versus placebo and daily GH in adult GHD in a randomized phase 3 trial (J Clin Endocrinol Metab 2020, PMID 32022863). By contrast, evidence for GH in healthy older adults is weak and unfavorable: the landmark Rudman study (N Engl J Med 1990, PMID 2355952) reported body-composition changes in men over 60 but was small and uncontrolled for clinical endpoints, and a systematic review (Liu et al., Ann Intern Med 2007, PMID 17227934) concluded GH produces only small body-composition changes in the healthy elderly while increasing adverse events, and cannot be recommended as anti-aging therapy. Claims of fat loss, muscle gain, or longevity in healthy or athletic populations are not supported by robust controlled human outcome data.

Human evidence comes mainly from early-phase ConjuChem trials in healthy adults. Teichman et al. (JCEM, 2006) reported that single subcutaneous doses produced dose-dependent, sustained elevations of GH and IGF-1, with IGF-1 remaining above baseline for several days and repeated weekly/biweekly dosing maintaining elevated IGF-1. Ionescu and Frohman (JCEM, 2006) showed that despite continuous GHRH-receptor stimulation, GH secretion remained pulsatile in healthy men. Preclinical support includes Alba et al. (Am J Physiol Endocrinol Metab, 2006), where once-daily CJC-1295 normalized growth in GHRH-knockout mice, and Sackmann-Sala et al. (Growth Horm IGF Res, 2009), which characterized GH/IGF-1-axis-driven serum protein changes. Crucially, there are no published controlled trials demonstrating clinical outcomes (body composition, strength, fat loss, anti-aging, or healing) in humans; the human data establish a pharmacodynamic GH/IGF-1 effect, not proven therapeutic benefit, and the program was discontinued without an approved indication.

Documented adverse effects, drawn largely from the healthy-elderly trials and GHD populations, include fluid retention and edema, arthralgias and joint swelling, carpal tunnel syndrome, and impaired glucose tolerance or new-onset diabetes due to GH-induced insulin resistance (Liu 2007, PMID 17227934). Acromegaly-like features and gigantism follow chronic GH excess. Long-term safety signals exist: the French SAGhE analysis and related cohorts raised concern about excess circulatory/cerebrovascular mortality after childhood GH treatment, prompting an FDA safety review, though the larger pooled SAGhE cohort (Lancet Diabetes Endocrinol 2020) provided more reassuring overall mortality data; the question of long-term cardiovascular and neoplastic risk remains incompletely resolved. GH is contraindicated in active malignancy, acute critical illness, and proliferative diabetic retinopathy. Non-prescription "GH" products and gray-market vials carry additional risks of misidentification, contamination, and incorrect labeling that are not characterized in any controlled study.

In the short early-phase human studies, the most consistently noted effects were injection-site reactions and transient flushing; sustained IGF-1 elevation also raises theoretical concerns common to GH-axis stimulation, such as fluid retention, joint discomfort, carpal-tunnel-type symptoms, and reduced insulin sensitivity. Long-term human safety is essentially uncharacterized: no large or long-duration controlled trials were completed, and chronically elevated GH/IGF-1 is a biologically plausible (though unproven for this compound) concern for promoting growth of existing neoplasms. Real-world risk is compounded by the fact that material sold as "CJC-1295 DAC" is unregulated and may vary in purity, identity, or sterility. No dosing or administration guidance is provided here.

Recombinant somatropin is FDA-approved (first approved 1985–1987) for specific indications including pediatric GH deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature, idiopathic short stature, chronic renal insufficiency, adult GH deficiency, and HIV-associated wasting; non-approved uses such as anti-aging, bodybuilding, or athletic enhancement are off-label and, in the US, distribution for such uses is specifically restricted by law. GH is a prohibited substance in and out of competition under the World Anti-Doping Agency (WADA) code.

CJC-1295 (with or without DAC) is not approved by the FDA or any major regulator for any use; clinical development was discontinued and it is treated as an unapproved/investigational substance, with U.S. authorities also flagging it as unsuitable for pharmacy compounding. It is prohibited in sport at all times by the World Anti-Doping Agency as a GH-releasing factor under Category S2 of the Prohibited List.